always online......
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed I expect news this week confirming successful (hopefully !) restart of production and beginning of stockpiling finished dried/screened/bagged high purity large flakes graphite in preparation of first shipments to our european off-taker "Possehl". I wont hide my optimism regarding the capacity of the refurbished mine, I follow the graphmada mine since the 2013-2014 stratmin (previous owners) days, and given the high quality thoroughly thought extensive refurbishment work done and thanks to our experienced and graphite mining/processing expert general manager of Graphmada Mr Wilhelm Reitz, I am confident that the newly refurbished mine will exceed the conservative management targets (6000tpa @ 94% purity). IMO the market will be more than surprisingly pleased over the coming weeks and months. This is it for the malagashy large flakes mine Graphmada ! I will go out on a limb and predict 4.5c+ share price re-rate over the coming two weeks that will include hopefully some nice company announcement surprises for Mr market ! Very exciting times ahead of us, IMO patient investors will be highly rewarded. Happy multi-bagger graphite and lithium investing to all !
https://hotcopper.com.au/threads/chart_ta.3773130/page-608?post_id=32617012#.Wt3Qv0xuKM9
Support & Resistance
2nd Resistance Point
0.032
1st Resistance Point
0.030
Last Price
0.029
1st Support Level
0.028
2nd Support Level
0.028
https://www.barchart.com/stocks/quotes/BSM.AX/opinion
30 Apr 2018 Report (Quarterly)
https://www.marketindex.com.au/asx/bsm
GraphmadaGraphite Mine 100% owned, debt free, fully recommissioned large flake graphite mine producingpremium graphite concentrates
• 40 year mining & environmental permits
• 20 year landholder agreements
• ~90% in-situ large flake graphite
• Off-take agreement in place
• Established logistics & infrastructure 382kt of contained graphite estimated (JORC)
• Primary Deposit (Mahefedok) 3.5 Mt @ 4.2% TGC1
• Secondary Deposit (Loharano) 5.7 Mt @ 4.1% TGC2
• Exploring Mahela & Andapa • Ambatofafanadeposit delineated
Exceptional grades of up to 7.08% Li2O
https://www.asx.com.au/asxpdf/20180416/pdf/43t7hkxjy5p6j7.pdf
Overall Average:
72% Buy
https://www.barchart.com/stocks/quotes/BSM.AX/opinion
NORTHERN IRON’S CORPORATE DEVELOPMENT TEAM
VISITS CHINA ON BUSINESS DEVELOPMENT MISSION
VANCOUVER, BRITISH COLUMBIA, CANADA – November 24, 2016.
Northern Iron Corp. ("Northern Iron” or the “Company”) (TSX-V: NFE)
(FRANKFURT: N8I) today announced that James Walker, CEO and Michael Hepworth VP
Corporate Development will be visiting automotive, battery and cathode manufacturers in
Western China during the last week of November. The objective of the trip is to interest these
manufacturers in investing in Northern Iron’s lithium properties in the US and securing a reliable
supply of lithium for their future needs.
The meetings are enabled by Northern Iron’s previous investment in building a wide network of
mining and minerals industry participants in China since 2011 and NFE’s two newest directors
who have extensive relationships with industrial and minerals consumers across Asia.
According to China’s Association of Automotive Manufacturers, China already leads the world
in the numbers of electric vehicles on the road. The EV Sales Blog reports that most lithium
ion batteries are currently made in Asia and China’s lithium consumption will grow in line
with stepped up production of batteries for these vehicles. This growth is driven largely by the
country’s focus on dramatically reducing emissions, necessitated by its New Energy Plan.
Basil Botha, Chairman and President of NFE said; “China is already the world’s largest
consumer of lithium and is currently facing an undersupply situation. The last few months have
seen significant deals in this space; deals engineered by Chinese companies looking for
security of supply and lithium industry participants looking for investment dollars and off-take.
We have access to many of these users and are hopeful of securing strategic investment and
off-take agreements over the coming months.”
About Northern Iron Corp.
Northern Iron Corp has 3 highly prospective lithium properties in Nevada and Arizona.
Jackpot Lake –Moapa Valley, Nevada
• 100% owned -2800 acres – 140 claims;
• 35 km NE of Las Vegas;
• 1976 USGS completed 129 core samples;
• Spectrographic and atomic-absorption analyses of 135 stream sediment
samples confirmed potential for lithium mineral deposits;
• Highest Lithium value was 550ppm, average 175 ppm.
Wilcox Playa –Arizona
• 1400 acres on shore of Wilcox Playa – Dry lake bed
• In 1976 USGS identified this area as one of the most prospective locations for lithium
brines and highly analogous to Clayton Valley
• USGS has identified a 22 sq. mile anomaly with high electrical conductivity, interpreted
as subsurface brine field with no hydrological outlet.
Little Rock Lithium Target - Yavapai County – Arizona
• High grade, lithium rich lacustrine clay
• Target is 2500 metres along strike ~ 20 metres thick
• Identified via electromagnetic survey in 2007
o Large, highly electrically conductive body
o Clay-altered rhyolite tuff.
• Grab sample 172 ppm Li
o Clayton Valley sediments are between 73 and 220ppm
Timothy Marsh PHD, P. Eng QP prepared the disclosures and reports related to these projects.
Northern Iron is also the owner of five iron (magnetite) properties in the Red Lake District in the
Province of Ontario. The Red Lake District is an established mining region where Northern Iron
has two near term development projects, the past producing Griffith mine and the Karas
property.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of
this release. No stock exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
For further information, please contact:
Basil Botha
President & CEO
Northern Iron Corp.
Tel: 604-566-8570
Fax: 604-602-9868
Email: bbotha@northernironcorp.com
Website: www.northernironcorp.com
For up to the minute news, industry analysis and feedback follow us on Facebook, Twitter,
LinkedIn, Google Plus and YouTube.
News 24.November 2016: http://media.wix.com/ugd/f57d32_67500c72228a49eaa0b86bde2fa9b934.pdf
Tesla shareholders approve SolarCity merger
http://seekingalpha.com/news/3225574-tesla-shareholders-approve-solarcity-merger
Published on November 13th,2016 Cannabis Science targets rapid expansion
Company targets over 1,000 acres in California and Nevada following election
Published on November 13th, 2016
Both California and Nevada voted to legalize marijuana for recreational adult use, which carries a host of benefits for Cannabis Science, as it allows more pathways for customers to attain the company's products. (Martijn, Flickr/Creative Commons)
IRVINE, Calif. — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is prepared to move in on new opportunities in California and Nevada markets following the election cycle. The Company is now targeting over 1,000 acres in California and Nevada for property and drug development programs. The post-election plan includes new products, new dispensaries, and new strategic agreements.
“After closing the last land deal we announced for over 300 acres, we are now on to something much larger on a combined scale. This land package goes right in line with our other large deals in California and Nevada. These land deals put us in a very favorable position for high growth moving forward. Coupled with completing our in-house laboratory, new drug programs, and our new website, we have some very exciting developments coming in the near future and we feel ready to meet the demands of more patients than ever before, and the timing couldn’t be better. With the tremendous support for Proposition 64 and other pro-cannabis initiatives across the nation Cannabis Science is positioned to become a market leader,” said Director, President, CEO & Co-Founder, Raymond C. Dabney.
Both California and Nevada voted to legalize marijuana for recreational adult use, which carries a host of benefits for Cannabis Science, as it allows more pathways for customers to attain the company’s products. Considering that California alone has the sixth largest economy in the world in terms of GDP, this opens a very large market for the company to reach.
Recently, articles have been released stating that cannabis sales in Colorado are slated to exceed alcohol sales only a couple of years’ post-legislation. In California’s much larger market, this type of consumer support in the cannabis industry has huge potential to drive Cannabis Science’s bottom line.
In preparation, the company has been rapidly expanding its drug development land deals in order to produce more products and meet demand increases. Additionally, the company is negotiating distribution deals with new dispensaries across the state to cast a wider net and reach more patients. The company’s most recent new products, including a pain relief product, an immune system bolsterer, and a sleep aid, are very accessible, even to first-time patients.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
–Cannabis Science, Inc.
via EINPresswire.com
- See more at: https://www.morningagclips.com/cannabis-science-targets-rapid-expansion/#sthash.ynIkZrZk.dpuf
Thanks.....GLTA.....CBIS..
Here’s Our Take On Cannabis Science Inc (OTCMKTS:CBIS)
By Chris Sandburg / in Biotech & Pharma, Momentum Stocks, Sector Watch, Stocks / on Friday, 04 Nov 2016 02:09 A
https://www.insiderfinancial.com/heres-our-take-on-cannabis-science-inc-otcmktscbis/118071/
Capitol Alert November 5, 2016 9:45 AM
Peter Thiel opens wallet for pot legalization in California
How much weed can you carry now that California has legalized marijuana? You might be surprised 1:49
Proposition 64 establishes one ounce of marijuana, or 8 grams of cannabis concentrates, as the legal limit for recreational pot possession for adults over the age of 21. Here are examples of actual amounts of products someone could carry now that California voters approved the ballot measure on Tuesday, Nov. 8. Sharon Okada sokada@sacbee.com
By Christopher Cadelago
ccadelago@sacbee.com
Peter Thiel, the Silicon Valley billionaire who co-founded PayPal and has become an outspoken supporter of Republican presidential candidate Donald Trump, has cut a big check to the California campaign to legalize recreational pot.
Thiel contributed $300,000 to Proposition 64, which would allow adults to consume cannabis, possess one ounce and grow six plants.
He becomes the largest marijuana investor to give to the measure. Through his venture capital firm, Thiel launched a multimillion-dollar investment in Privateer Holdings, a firm with stakes in marijuana businesses.
Thiel contributed $70,000 to the failed legalization bid, Proposition 19 in 2010, a donation that also came late in the campaign. He also gave $25,900 that year to Republican Meg Whitman’s failed gubernatorial campaign.
In April, he maxed out ($56,400) to Democratic Lt. Gov. Gavin Newsom’s gubernatorial campaign, after donating $13,600 to Newsom in 2014. Newsom is Proposition 64’s primary backer.
A conservative libertarian who endorsed Ron Paul for president in 2012, Thiel spoke in support of Trump in July at the Republican National Convention in Cleveland. He contributed $1.25 million to Trump’s campaign last month. In a speech this week at the National Press Club, Thiel stressed that he doesn’t agree with everything Trump has said and done – “and I don’t think the millions of other people voting for him do, either.”
“It’s not a lack of judgment that leads Americans to vote for Trump; we’re voting for Trump because we judge the leadership of our country to have failed,” he said.
Christopher Cadelago: 916-326-5538, @ccadelago
Read more here: http://www.sacbee.com/news/politics-government/capitol-alert/article112777458.html#storylink=cpy
Real-Time Best Bid & Ask0.0395 / 0.04
Real-Time Best Bid & Ask 0.0341 /0.10
http://www.otcmarkets.com/stock/CBIS/quote
Plus 16,22 %,today CBIS Trade in Germany
http://www.wallstreet-online.de/aktien/cannabis-science-aktie/kurse
Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over 1,000 Acres Targeting Property/Drug Development in California and Nevada as Industry Opens Up Nachrichtenquelle: Marketwired | 10.11.2016, 17:24 | 98 | 0 | 0 IRVINE, CA--(Marketwired - Nov 10, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is prepared to move in on new opportunities in California and Nevada markets following the election cycle. The Company is now targeting over 1,000 acres in California and Nevada for property and drug development programs. The post-election plan includes new products, new dispensaries, and new strategic agreements. "After closing the last land deal we announced for over 300 acres, we are now on to something much larger on a combined scale. This land package goes right in line with our other large deals in California and Nevada. These land deals put us in a very favorable position for high growth moving forward. Coupled with completing our in-house laboratory, new drug programs, and our new website, we have some very exciting developments coming in the near future and we feel ready to meet the demands of more patients than ever before, and the timing couldn't be better. With the tremendous support for Proposition 64 and other pro-cannabis initiatives across the nation Cannabis Science is positioned to become a market leader," said Director, President, CEO & Co-Founder, Raymond C. Dabney. try { Ads_TFM_AD('CADX1'); } catch(e) {} Both California and Nevada voted to legalize marijuana for recreational adult use, which carries a host of benefits for Cannabis Science, as it allows more pathways for customers to attain the company's products. Considering that California alone has the sixth largest economy in the world in terms of GDP, this opens a very large market for the company to reach. Recently, articles have been released stating that cannabis sales in Colorado are slated to exceed alcohol sales only a couple of years' post-legislation. In California's much larger market, this type of consumer support in the cannabis industry has huge potential to drive Cannabis Science's bottom line. In preparation, the company has been rapidly expanding its drug development land deals in order to produce more products and meet demand increases. Additionally, the company is negotiating distribution deals with new dispensaries across the state to cast a wider net and reach more patients. The company's most recent new products, including a pain relief product, an immune system bolsterer, and a sleep aid, are very accessible, even to first-time patients. About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission. Cannabis Science, Inc. Investor Relations Teresa Misenheimer teresa@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832 Wertpapier: Cannabis Science, Immunoclin Themen: Invest, Som, RVI Verpassen Sie keine Nachrichten von Marketwired Abonnieren Sie jetzt Ihren Lieblingsautor Ich habe die Allgemeinen Nutzungsbedingungen und die Datenschutzerklärung gelesen und stimmt diesen zu.Autor abonnierenWir respektieren Ihre Privatsphäre, es werden keine Daten an Dritte weitergegeben!Verpassen Sie nichts mehr aus der wallstreet:online Redaktion!Newsletter kostenlos abonnieren Schreibe Deinen Kommentar Um einen Kommentar zu schreiben, müssen Sie sich anmelden! Anmelden Jetzt kostenlos registrieren Kein Mitglied? Werden Sie Teil Deutschlands größter Finanz-Community. Kommentar abschicken Disclaimer Die hier angebotenen Beiträge dienen ausschließlich der Information und stellen keine Kauf- bzw. Verkaufsempfehlungen dar. Sie sind weder explizit noch implizit als Zusicherung einer bestimmten Kursentwicklung der genannten Finanzinstrumente oder als Handlungsaufforderung zu verstehen. Der Erwerb von Wertpapieren birgt Risiken, die zum Totalverlust des eingesetzten Kapitals führen können. Die Informationen ersetzen keine, auf die individuellen Bedürfnisse ausgerichtete, fachkundige Anlageberatung. Eine Haftung oder Garantie für die Aktualität, Richtigkeit, Angemessenheit und Vollständigkeit der zur Verfügung gestellten Informationen sowie für Vermögensschäden wird weder ausdrücklich noch stillschweigend übernommen.wallstreet:online hat auf die veröffentlichten Inhalte keinerlei Einfluss und vor Veröffentlichung der Beiträge keine Kenntnis über Inhalt und Gegenstand dieser. Die Veröffentlichung der namentlich gekennzeichneten Beiträge erfolgt eigenverantwortlich durch Autoren wie z.B. Gastkommentatoren, Nachrichtenagenturen, Unternehmen. Infolgedessen können die Inhalte der Beiträge auch nicht von Anlageinteressen von wallstreet:online und / oder seinen Mitarbeitern oder Organen bestimmt sein. Die Gastkommentatoren, Nachrichtenagenturen, Unternehmen gehören nicht der Redaktion von wallstreet:online an. Ihre Meinungen spiegeln nicht notwendigerweise die Meinungen und Auffassungen von wallstreet:online und deren Mitarbeiter wider. (Ausführlicher Disclaimer) × Artikel versenden Cannabis Science Targets Rapid Expansion as it Opens New Negotiations for over 1,000 Acres Targeting Property/Drug Development in California and Nevada as Industry Opens Up IRVINE, CA--(Marketwired - Nov 10, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS